← All Axsome Therapeutics, INC filings

Axsome Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
AXSM
Axsome Therapeutics, INC
10-K: Axsome Therapeutics Reports Strong 2025 Revenue Growth, Advances CNS Pipeline
Axsome Therapeutics achieved significant revenue growth in 2025, driven by commercial product sales, while advancing its robust CNS pipeline with key regulatory milestones and new acquisitions.
NASDAQ
AXSM
Axsome Therapeutics, INC
10-K: Axsome Therapeutics Reports 2024 Financial Results, Highlights Pipeline Progress
Axsome Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides an overview of its commercial products and development programs.
NASDAQ
AXSM
Axsome Therapeutics, INC
10-K: Axsome Therapeutics Navigates Commercial Growth and Pipeline Development: 2023 10-K Filing
Axsome Therapeutics' 2023 10-K filing highlights commercial progress with Auvelity and Sunosi, alongside ongoing clinical development programs.